CuriMeta

Accuronix Therapeutics Inc is a cutting-edge biotechnology company based in St. Louis, MO, dedicated to developing innovative cancer therapies. Utilizing a unique drug-targeting technology, the company focuses on addressing the most challenging issues in cancer treatment, with an initial emphasis on pancreatic cancer. With strategic partnerships with renowned institutions like Washington University and the University of Pennsylvania, Accuronix Therapeutics aims to develop groundbreaking oncology therapies that selectively target -2 receptors, which are known to be overexpressed on cancer cells. Led by President and CEO Bradley T. Keller, Ph.D., the company is committed to pushing the boundaries of cancer therapy and making a significant impact in the field of oncology.Generated from the website

AIDS Clinical Trials Unit at the Washington University Medical Center conducts clinical research trials for the treatment of HIV/AIDS and its complications. Since 1987, the unit has been a participant in the AIDS Clinical Trials Group, which is funded by the National Institute of Allergy and Infectious Diseases. AIDS Clinical Trials Unit also offers community outreach, educational and consulting services for health care professionals. It has screened more than 4,000 HIV-infected individuals since its establishment. Over 1,500 volunteers have participated in its educational programs. Incorporated in 1962, the Washington University Medical Center is a medical teaching center that includes the Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis Children s Hospital, Barnard Hospital, Siteman Cancer Center and the Central Institute for the Deaf. It maintains a presence in St. Louis, and is a part of the Washington University in St. Louis.

Cofactor Genomics is a leading biotech company based in Saint Louis, MO, specializing in predictive diagnostics for cancer patients. Their groundbreaking OncoPrism assay accurately predicts patient response to immunotherapy, revolutionizing the field of precision medicine. With partnerships with over 24 healthcare systems, Cofactor is at the forefront of the national PREDAPT trial, studying 11 solid tumor cancers and providing clinicians and patients with better tools for treatment decisions. Driven by a multidimensional approach, Cofactor Genomics is dedicated to advancing human health and precision medicine. Their diagnostic pipeline includes ongoing clinical studies and validation for various indications in immune-oncology, such as cervical cancer, colorectal cancer, and non-small-cell lung cancer. With a focus on predictive biomarkers and cutting-edge technology, Cofactor is shaping the future of cancer treatment and improving patient outcomes.Generated from the website